Portfolio 2026 · A Glimpse

Kyle Scallon

VP, Associate Creative Director · Art

Creative leader with over a decade across branding, advertising, publishing, and marketing research — including 6+ years leading HCP and patient campaigns in pharma. Art director, designer, illustrator. A selection of public-facing work is below; the complete book is available on request.

Selected Work

A curated public sample. Launched and external-facing projects only — full case studies live in the complete book.

One Liver to Love — unbranded liver cancer campaign

One Liver to Love

Live · Public Unbranded Liver Cancer Art / Creative Direction

An award-winning unbranded liver-cancer initiative built with advocacy partners — warm, character-led CGI storytelling and a resource hub designed to feel human and easy to return to. What's good for you is good for your liver.

Gold Aster 2025 Shorty Impact 2024 — Silver + Audience Honors
Power of Data — ICLUSIG HCP campaign

Power of Data

Launched HCP · Leukemia Art / Creative Direction

An HCP campaign that turns long-term evidence into direction, not overload — light, motion, and momentum scaled across congress, print, and digital.

Ficerafusp alfa MOA illustration

Ficerafusp alfa · MOA

Live Scientific Illustration Art Lead / Illustrator

A rapid-turn mechanism-of-action illustration translating tumor-penetration science into a clear, presentation-ready visual for ASCO and investor storytelling.

The Luking Glass — unbranded lupus awareness concept

The Luking Glass

Concept Unbranded Lupus Awareness Art / Creative Direction

An unbranded lupus awareness concept rooted in health equity and visibility — turning an everyday ritual into a moment of recognition and self-advocacy, carried by striking, emotionally charged visual craft.

The Complete Book

My full range.

The full portfolio includes deeper case studies, character and scene development, motion work, and select in-progress and confidential pharma campaigns — shared on request under NDA where needed.

Kyle Scallon
Portfolio 2026 · Confidential beyond this page